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Germline CDH1 point or small frameshift mutations can be identiﬁed in 30–50% of hereditary diffuse gastric
cancer (HDGC) families. We hypothesized that CDH1 genomic rearrangements would be found in HDGC and
identiﬁed 160 families with either two gastric cancers in ﬁrst-degree relatives and with at least one diffuse gas-
tric cancer (DGC) diagnosed before age 50, or three or more DGC incloserelatives diagnosed at any age. Sixty-
seven carried germline CDH1 point or small frameshift mutations. We screened germline DNA from the 93
mutation negative probands for large genomic rearrangements by Multiplex Ligation-Dependent Probe
Ampliﬁcation. Potential deletions were validated by RT–PCR and breakpoints cloned using a combination of
oligo-CGH-arrays and long-range-PCR. In-silico analysis of the CDH1 locus was used to determine a potential
mechanism for these rearrangements. Six of 93 (6.5%) previously described mutation negative HDGC pro-
bands, from low GC incidence populations (UK and North America), carried genomic deletions (UK and
North America). Two families carried an identical deletion spanning 193 593 bp, encompassing the full CDH3
sequence and CDH1 exons 1 and 2. Other deletions affecting exons 1, 2, 15 and/or 16 were identiﬁed. The stat-
istically signiﬁcantover-representation of Alus around breakpoints indicatesit as a likelymechanism forthese
deletions. Whenall mutationsanddeletionsare considered, the overall frequency ofCDH1alterationsinHDGC
is 46% (73/160). CDH1 large deletions occur in 4% of HDGC families by mechanisms involving mainly non-
allelic homologous recombination in Alu repeat sequences. As the ﬁnding of pathogenic CDH1 mutations is
useful for management of HDGC families, screening for deletions should be offered to at-risk families.
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Hereditary diffuse gastric cancer (HDGC) is an autosomal
dominant disorder that accounts for ,1% of all cases of
gastric cancer (GC). Although uncommon, this disease consti-
tutes an important health issue due to its severity, its high
penetrance, early age at presentation and the unavailability
of effective screening tools. Diffuse gastric cancer (DGC) is
the most important cause of cancer lethality in mutation posi-
tive HDGC families with lobular breast cancer being a second-
ary medical concern (1).
Heterozygous germline point or small frameshift mutations
in E-cadherin gene (CDH1) [OMIM þ192090], a calcium-
dependent cell-to-cell adhesion molecule and a tumor suppres-
sor protein, are the only germline molecular defect associated
with HDGC (2–4). Overall, carriers of CDH1 germline
mutations have a cumulative GC risk, before age 75, of 40–
67% for men and 63–83% for women and a risk for lobular
breast cancer of 39–52% (5,6). Clinical expression of the
disease often occurs before the third decade of life (1), but pre-
clinical multifocal tumors, which may have the potential for
metastatic spread, are already present in the stomachs of
young asymptomatic CDH1 mutation carriers (7,8).
Clinical criteria have been established, in 1999, by the Inter-
national Gastric Cancer Linkage Consortium (IGCLC) to
select families for mutation screening in the CDH1 gene,
based mainly on early age of disease presentation and
diffuse histology of the tumors (9). These have been later
adapted in an attempt to enlarge the population to which this
screening could apply, in countries with low incidence of
GC (10). Overall, 30–40% of HDGC families harbor CDH1
germline mutations, but this frequency is highly variable
between countries with different incidences of GC, with low
incidence countries like UK, North America and Canada, dis-
playing nearly 50% of HDGC mutation positive families,
while high incidence countries like Portugal and Italy, display-
ing around 10% of HDGC mutation positive families (4,6,11).
Approximately two-thirds of families, screened worldwide,
remain genetically unexplained and the concern related with
the management of CDH1 mutation negative gastric cancer
families persists. Since the required samples for full genome
linkage, in any GC family, are difﬁcult to obtain, a candidate
gene approach to identify novel susceptibility genes has been
more frequently used. Putative tumor suppressor genes, which
are commonly inactivated in sporadic GC and/or associated
with GC development, could also represent good candidate
susceptibility genes to familial GC. Previous studies including
ours, however, have lead us to rule out RUNX3, Caspase-10,
SMAD4, HPP1, and Desmoglein 2 as major GC predisposition
genes in families with aggregation of gastric carcinoma
(12–14). Virtually all diffuse gastric carcinomas, both heredi-
tary and sporadic, independently of whether they carry a
CDH1 mutation, display identical morphological features as
well as aberrant patterns of expression of E-cadherin (unpub-
lished data). As no other gene has been so far shown to play a
major genetic role in the disease, we hypothesize that other
genetic events at the CDH1 locus, potentially missed by stan-
dard screening techniques, such as large genomic rearrange-
ments, deletions or insertions could be found in families
with multiple cases of DGC. Examples of this type of
molecular alterations have been recently reported for other
cancer associated syndromes. Large genomic rearrangements
have been described in hMLH1 and hMSH2 in 10–20% of
HNPCC mutation negative families, in APC in 15% of FAP
mutation negative families and in lower frequencies in
BRCA1 and BRCA2 in breast cancer families initially ident-
iﬁed as negative, as well as in CDKN2A in melanoma negative
families (15–21).
Based on these observations, we aimed at characterizing
CDH1 genomic rearrangements in a large population of
HDGC patients, negative for CDH1 point mutations. More-
over, by using a larger series of families screened for CDH1
point mutations and rearrangements, in ﬁve reference centers
world-wide and arising in countries with different GC inci-
dence rates, we aimed at clarifying the frequency of CDH1
germline alterations and its relationship with GC incidence
as well as with clinical criteria for selection of patients at risk.
RESULTS
Multiplex ligation-dependent probe ampliﬁcation analysis
for the CDH1 gene
We collected, from ﬁve reference centers, 93 DNA samples
from families with aggregation of DGC and negative for
CDH1 germline point mutations. These families were selected
based on their risk to carry a germline alteration in CDH1 and
the clinical criteria described in Materials and Methods
section.
We found that six out of the 93 (6.5%) probands showed
abnormal multiplex ligation-dependent probe ampliﬁcation
(MLPA) features when compared with the controls, displaying
an 70% signal reduction in one or more exons of the CDH1
gene and, suggesting the presence of large deletions affecting
the CDH1 locus (Fig. 1, Table 1). No abnormalities were
observed in the remaining 87 probands.
After reproducing these results in an independent MLPA
reaction, we veriﬁed that four probands (families 1 to 4) pre-
sented deletions at the 50-end of the gene: in three probands
deletions encompassed at least exon 1, intron 1 and exon 2
and, in one proband a smaller deletion that encompassed one
of the three probes designed for CDH1 exon 1 was found.
The remaining two probands (families 5 and 6) displayed del-
etions at the further 3’end of the gene: in one proband a del-
etion of the genomic sequence encompassing exons 14 and
16 was observed, an in the other a deletion of exon 16 only
was observed (Fig. 1).
Fine mapping of the deletions breakpoints
A combination of array CGH and PCR was utilized to map the
putative breakpoints in ﬁve of the six probands (Fig. 2). The
array CGH indicated the regions of chromosome 16 at
which the breakpoints were located. PCR primers were then
designed to span the breakpoints and the resulting PCR pro-
ducts sequenced (Table 2). Family 1 and family 2 showed
identical MLPA patterns as well as virtually identical array
CGH results. Sequencing of the breakpoint revealed that
these two families harbored an identical 193 593 bp deletion
encompassing the full sequence of CDH3 and extending to
1546 Human Molecular Genetics, 2009, Vol. 18, No. 9position IVS2þ57 595 in CDH1. Family 3 was found to carry
a 5671 bp deletion with breakpoints at position 23809
upstream of the CDH1 transcription start site (TSS) and at pos-
ition IVS2þ742 in CDH1. Family 4 harbored a 150 bp del-
etion encompassing the TSS of CDH1, with breakpoints
located 125 bp upstream and 25 bp downstream of the TSS.
Array CGH was not done for this proband since the PCR
encompassing CDH1 exon 1 produced both a normal sized
and a shorter band that was visible by dHPLC and further
used to clone the breakpoints for the deletion by direct sequen-
cing. Family 5 carried an 8078 bp deletion ranging from
IVS13-2738 to 20 bp downstream of the stop codon of
CDH1, as conﬁrmed by long-range PCR using speciﬁc
primers ﬂanking the breakpoints (Fig. 3A). Family 6 was
found to carry an 828 bp deletion ranging from
IVS15þ3097 to 223 bp downstream of the stop codon of
CDH1 (Fig. 3B).
Bioinformatics analysis of breakpoints and deletion
containing sequences
Assuming that deletions are more likely to occur due to
recombination events, we analyzed the genomic sequences
ﬂanking the boundaries of these ﬁve deletions, which are pre-
dicted to constitute target regions for breaks and recombina-
tions to occur. We performed a search for Alu elements
which have been reported to mediate non-allelic recombina-
tion events in several other malignancies. Evidence for non-
homologous end joining (NHEJ) and non-allelic homologous
recombination (NAHR) has been described in atypical NF1
microdeletions. These deletions were traced back to short
sequences with similarities to Alu elements near the deletion
junction (22). Moreover, deletions in the PMP22 gene have
been described to be a product of homologous recombination
between AluS elements present in intronic regions of the
Figure 1. MLPA output from the six HDGC families carrying germline deletions of the CDH1 locus. The ﬁrst 17 bars represent signal obtained with MLPA
probes within the CDH1 gene. Please note that for exon 1, three probes were used (1a, 1b and 1c). CDH1 deletions are represented, in the graph, by smaller bars
marked with arrows. Bars on the right hand-side represent results obtained with control probes for MLPA (n ¼ 15).
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cryptic sequences recognizable by the RAG1/2 recombinase
near the breakpoints and the insertion of P and/or N nucleo-
tides in the rejoining sites. Such sequence features, reminis-
cent of V(D)J recombination sites, are expected to indicate
whether cleavage by the RAG1/2 recombinase may occur
near these joining sites (24,25).
In three families carrying two different deletions we found
that deletions overlap Alu repeats (Table 3). In families 1
and 2, bearing the same deletion at chr16:67193822–
67387415, both deletion boundaries fall within annotated
Alu repeats, AluSp near the start and AluSg near the end.
The sequences of the two repeats are highly similar (percen-
tage identity .75%) (Table 3, Fig. 4A). In family 3, carrying
a deletion at chr16:67324886–67330557, the start of the del-
etion maps inside an AluSx repeat while the end map into a
repeat AluSg and, the sequences of these two repeats display
an identity of 80% (Table 3, Fig. 4B).
For the deletion at chr16:67328695–67328844, present in
family 4, an AluJo repeat is present 304 bp upstream from
the start of the deletion, and another AluJo is present
1497 bp downstream the end of the deletion. The closest
repeat external to the deletion is a MIR named MIRb,
1235 bp downstream of the end-point but no sequence identity
can be seen in the 2150/þ50 and 250/þ150 bp fragments
centered, respectively, on the start and the end of the deletion.
An interesting feature of this 150 bp deletion is the presence of
microsinteny/microhomology around the breakpoints due to
the presence of ﬁve nucleotides sequence (CTCTC) between
the upstream and downstream breakpoints.
Family 5 displays a deletion at chr16:67416845–67424923
that does not overlap Alu repeats, although it occurs in the
proximity of this type of repetitive regions (Table 3). The
closest repeats both upstream and downstream are AT rich
sequences, 300 bp distant from the deletion (Fig. 4C). More-
over, 344 bp upstream of the deletion start a FLAM_C repeat
Figure 2. Array CGH proﬁles obtained for HDGC families carrying large CDH1 deletions. Examples are shown for four of the six families. See Tables 2 and 3
for details on the deletion found in each family. Deletions are represented by dense areas of green dots on the left side of each panel. Vertical thick gray bars on
the left represent genes in the genomic area surrounding the CDH1 locus and corresponding gene symbols are also shown. Smaller deletions in families#3 and #5
are pointed with black arrows. Please note the scale in Mb on the right, for chromosome position.
Table 1. Table summarizing HDGC families analyzed for large CDH1 rearrangements (gray columns) and compilation of frequency of CDH1 alterations indi-
cating geographic origin grouped by GC incidence rates
Incidence Origin (n) Rearrangement analysis Deletion (%) CDH1 positive (%) CDH1 negative (%)
Low North America (92) 49 4 (8.2) 47 (51.1) 45 (48.9)
UK (33) 18 2 (11.1) 17 (51.5) 16 (48.5)
Holland (1) 0 0 1 (100.0) 0
Total (126) 67 6 (9.0) 65 (51.6) 61 (48.4)
Moderate Germany (16) 12 0 4 (25.0) 12 (75.0)
Total (16) 12 0 (25.0) 2 (75.0)
High Portugal (15) 12 0 3 (20.0) 12 (80.0)
Italy (3) 2 0 1 (33.3) 2 (66.6)
Total (18) 14 (22.2) 14 (77.8)
Total (160) 93 6 (6.5)
a 73 (45.6) 87 (54.4)
aThis frequency represents 6/93 CDH1 deletions found in negative families. The overall frequency of large CDH1 deletions is 3.8% (6/160).
Table 2. Summary of HDGC families displaying CDH1 germline deletions
ID Ancestry GC incidence Other cancers (age) Genomic rearrangement
Family 1 Northern European Low LBC (61) Del exon 1–2 (193 593 bp)
Family 2 Canadian Low Del exon 1–2 (193 593 bp)
Family 3 Eastern European Low PCa (43) Del exon 1–2 (5671 bp)
Family 4 Southern European Low LCa (nd), PCa (42) Del 50-UTR-exon 1 (150 bp)
Family 5 Central European Low Unknown Del exon 14–16 (8078 bp)
Family 6 Central European Low Unknown Del exon 16 (828 bp)
LBC, lobular breast cancer; PCa, pancreatic cancer; LCa, liver cancer.
1548 Human Molecular Genetics, 2009, Vol. 18, No. 9exists and 442 bp downstream of the endpoint there is an AluJb
sequence (Table 3). The alignment of the 2150/þ150 bp sur-
rounding the deletion ends did not show any identity.
The deletion in family 6, at chr16:67424298–67425126, is
unlikely to have been produced by homology-dependent
mechanisms, since a small (3 bp) sequence insertion at the
junction between the deletion breakpoints was identiﬁed
(Fig. 3B). For this deletion, the closest Alu repeats found on
both sides of the deletion are an AluSq 50 bp upstream and
an AluJb 239 bp downstream of the deletion’s start and end,
which share a sequence identity .77% (Table 3).
In a range of þ/25 Mb ﬂanking the ﬁve deletions reported
in this study, we did not ﬁnd evidence for the presence of
RAG1/2 consensus sequences accompanied or not by the
insertion of P and/or N nucleotides in the rejoining sites.
Nevertheless, the presence of Alus overlapping 6 out of the
12 points analyzed (the ends of the six deletion sequences)
is statistically signiﬁcant (z-score 3.3, P-value 0.0005) as
tested by performing a randomization analysis with 1000
random sampling of 12 random locations (see Materials and
Methods).
Clinical features of deletion-carrying HDGC families
The proband in family 1 was a 61-year-old female of European
Irish/German/Scottish/Danish ancestry presenting with lobular
Figure 3. Sequencing chromatogram of the mapped breakpoints in family 5 (A) and family 6 (B). Comparison with the human genome reference sequence. (A)
Deletion of 8078 bp without insertion of P or N nucleotides. (B) Deletion of 828 bp and insertion of a triplet at the breakpoint.
Table 3. Deletion coordinates and distance from deletion ends to the closest Alu containing sequences
Family ID Deletion coordinates Closest start Alu Closest start Alu distance Closest end Alu Closest end Alu distance
Family 1 chr16:67193822–67387415 AluSp overlap AluSg overlap
Family 2 chr16:67193822–67387415 AluSp overlap AluSg overlap
Family 3 chr16:67324886–67330557 AluSx overlap AluSg overlap
Family 4 chr16:67328695–67328844 AluJo 2304 AluJo 1497
Family 5 chr16:67416845–67424923 FLAM_C 2344 AluJb 442
Family 6 chr16:67424298–67425126 AluSq 250 AluJb 239
Human Molecular Genetics, 2009, Vol. 18, No. 9 1549breast cancer. Her daughter and son, as well as a grand-
daughter developed DGC at the age of 40, 37 and 28, respect-
ively, and are already diseased. The deletion was only looked
for in the proband that is currently alive.
In family 2, the proband, of unknown origin but currently
living in Canada, was a female who developed DGC at 38
and later at 43 years old and the only patient tested in this
family. Her two sisters also developed DGC at the ages of
30 and 35, respectively, but were not tested for the presence
of the same deletion.
The presence of the same deletion in two different families
could be explained two ways. Either of these families had a
common ancestor or the deletions arose independently. To
clarify this issue, we performed haplotype analysis with
seven microsatellite markers surrounding the CDH1 gene
and veriﬁed that an allele for each of the microsatellite
markers was common between the two families, demonstrat-
ing the existence of a common ancestor carrying this deletion
(Fig. 5).
The proband in family 3, was a 34-year-old female of Euro-
pean Lithuanian origin, with DGC. Her mother was also
affected by the same disease at uncertain age, and her grand-
father developed pancreatic cancer at the age of 43 and none
of them was tested for the deletion. The proband in family
4, was a 40-year-old male of Hispanic origin who developed
DGC at the age of 40. His 24-year-old brother died from
exactly the same disease and his father died at 42 with a pan-
creatic cancer, neither has been tested for the deletion. Carrier
tests have been performed in ten other family members and
one of which was positive.
In family 5, the proband was a patient of European ancestry,
who developed DGC at 33 years. His two sisters developed
DGC at 33 and 35 years. At least one second degree relative
developed GC, but no more information was available. So
far, only the proband was tested, but ﬁve other family
members are currently being tested for the presence of the del-
etion. As for family 6, the proband was a 51-year-old patient
of European ancestry who developed DGC. His mother died
of GC of unconﬁrmed histology at age of 52. Two sisters
were recently diagnosed with DGC by surveillance endoscopy,
although only one of them was tested for the deletion and
proved to be a carrier. This sister’s offspring, constituted of
two asymptomatic individuals, also tested positive for the del-
etion. Four other second degree relatives died of cancer, one
with DGC, two of GC of unknown histology and one of
lobular breast cancer.
Clinical criteria, frequency of CDH1 alterations
and GC incidence
In the present study, we analyzed 93 families based on two
clinical criteria: (i) three or more DGC in ﬁrst degree relatives
diagnosed at any age or; (ii) two or more GC in ﬁrst degree
relatives with at least one DGC diagnosed before age 50;
Figure 4. Analysis of sequences ﬂanking the deletion breakpoints. (A and B) Homology analysis of AluS type elements ﬂanking deletions in families 1, 2 and
3. (C) Ensembl based scheme displaying the repetitive elements ﬂanking the deletion in family 5.
1550 Human Molecular Genetics, 2009, Vol. 18, No. 9and found that 6.5% of these families carry large CDH1 germ-
line deletions.
With the purpose of clarifying the relative contribution of
germline CDH1 point mutations and deletions in a large
series of families fulﬁlling the aforementioned criteria, we col-
lected data not only on the 93 negative families, herein ana-
lyzed for genomic rearrangements, but also on 67 HDGC
families carrying CDH1 point mutations, from ﬁve different
reference centers, and originated from countries with low,
moderate and high GC incidence rates.
From the series of 160 probands, 73 (45.6%) were proved to
carry germline CDH1 alterations: 41.9% point mutations and
3.8% large deletions (Fig. 6).
In low incidence countries namely in the North America,
Canada, UK and Holland, the frequency of germline CDH1
alterations was 51.6%, while in moderate (Germany) and
high (Portugal and Italy) incidence countries the frequency
of alterations was 25 and 22.2%, respectively (Fig. 6). Large
deletions were only identiﬁed in countries with low incidence
of GC and account for 9% of all CDH1 alterations in HDGC
families from such countries (Table 1).
DISCUSSION
In this report, we demonstrate that germline large deletions
affecting the CDH1 locus are one of the mechanisms under-
lying HDGC. Our data supports the addition of MLPA based
screening for such deletions to clinical screening for CDH1
mutations.
The CDH1 locus, like the hMLH1, hMSH2, BRCA1, APC
and CDKN2A loci, is a region susceptible to genomic
rearrangements leading to increased cancer susceptibility
(18,19,21,26).
The analysis of deletions found in our HDGC patients,
revealed that two out of ﬁve deletions showed extensive
sequence identity between the two breakpoints, strongly
suggesting that NAHR was the mechanism of their formation
(Families 1, 2 and 3). The deletion breakpoints of these two
deletions fall within Alu repeats similar to what has been pre-
viously reported for hMLH1, hMSH2, BRCA1 and infre-
quently for APC (18,19,26). Alu repetitive sequences have
long been believed to give rise to genomic deletions promot-
ing recombinational instability (27). PMP22 deletions have
been described to be a product of homologous recombination
between intronic AluS elements in hereditary neuropathies
(23), but the type of Alu sequences involved in deleterious
deletions underlying cancer-associated syndromes have not
been systematically explored in the literature. Nevertheless,
at least one of the Alu sequences located at large deletion
breakpoints in hMLH1 gene are described to be of the
AluSx type (28). In our study, we analyzed the type of Alu
sequences associated with CDH1 large deletions in HDGC,
and found that six breakpoints overlap AluS elements: three
overlap AluSg, two overlap AluSp and one overlaps an
AluSx (Table 3).
One of the deletions herein identiﬁed occurs in a context
of microhomology and could have arisen by microhomology-
mediated recombination, a mechanism of NHEJ. This mech-
anism is associated with very short stretches of sequence
identity (a few bp) between the two ends of the breakpoint
junctions (29,30), rather than with long stretches of sequence
identity at these locations (31,32). Moreover, it involves the
double strand breakage of DNA followed by end joining in
the absence of extensive sequence homology. A similar
microhomology-mediated intra-strand repair mechanism has
been previously described to occur either in pathological
conditions such as trisomy in a family displaying an inverted
duplication/deletion of 2p25.1–25.3 (33) or in recombination
events underlying genomic variation during evolution (34).
The same putative mechanism underlying the type of del-
etion and end re-joining, found in this family, has been
described in a recent report where the treatment of mice,
Figure 5. Haplotype analysis of family 1 and family 2 probands. (A)
Scheme of chromosome 16 with reference to microsatellite markers used in
the haplotype analysis and to the breakpoints of the deletion. (B) Common
haplotypes displayed by probands of family 1 and family 2 and proving a
common ancestry. (C) Agarose gel of the PCR that allowed the mapping of
the deletion, showing similar band sizes for probands in both families.
Figure 6. Frequency of CDH1 alterations in a series of 160 HDGC families,
subdivided by GC incidence rates as well as by type of gene alteration (point
or small frameshift mutations and large deletions).
Human Molecular Genetics, 2009, Vol. 18, No. 9 1551with speciﬁc chemicals or radiation during late spermato-
genic stages, generates very short deletions, duplications,
or inversions with microhomology around breakpoints. The
ligation by NHEJ mediated by microhomology, is raised in
the aforementioned report, as the major path of repair (35),
and provides insight on how this speciﬁc CDH1 deletion
may have initially arisen.
Another of our deletions is unlikely to have been produced
by homology-dependent mechanisms, since a small sequence
insertion (3 bp) at the junction between the deletion break-
points was identiﬁed. Since no extensive homology exists in
the vicinity of breakpoints, it is likely that this deletion have
been mediated by NHEJ. Identical deletions involving small
insertions (3, 4, 6 bp), of unknown origin at the site of the
breakpoints, have been previously identiﬁed within copy
number variants (CNVs) breakpoint-region sequences, in
normal population (32,34).
In contrast to all other CDH1 deletions described so far in
this report, one does not seem to be caused by NAHR,
microhomology-mediated recombination or small sequence
insertions at the junction site. This deletion is ﬂanked by
upstream and downstream low complexity AT rich sequences,
as well as FLAM_C repeat and an AluJb sequence. Similar
features surrounding deletions have been previously described
to occur in CNVs described in apparently normal individuals
(34), but the mechanisms involved in their generation is not
known. The AT rich sequences could mediate a
microhomology-mediated deletion mechanism based on their
base composition bias, though further evidence would be
needed to prove this.
Deletions found in HDGC families mainly fall into three
separate classes: products of NAHR, in which recombination
between Alu containing sequences leads to deletion of the
sequence between them; products of microhomology-
mediated recombination, a mechanism of NHEJ; and results
of small insertions of unknown origin at the site of the break-
point junction. These deleterious deletions in CDH1 appear as
the pathogenic counterpart of apparently normal evolution
generated CNVs (32,34).
The probands studied (n ¼ 160) fulﬁlled clinically used cri-
teria for HDGC (see Materials and Methods). We found that
45.6% (73/160) of them displayed CDH1 alterations (Fig. 6).
In comparison, only 7/123 (5.7%) of the probands of families
who did not meet the above testing criteria, had point
mutations or small frameshift mutations, and none had del-
etions detectable through MLPA (data not shown). Based on
this analysis, we have demonstrated that the clinical criteria
herein used (three or more DGC in ﬁrst degree relatives diag-
nosed at any age or two or more GC in ﬁrst degree relatives
with at least one DGC diagnosed before age 50) will identify
most families with HDGC associated germline CDH1 altera-
tions, with a mutation pick up rate of 46%. Based on
these criteria, 4% of HDGC patients display large CDH1
germline deletions (Fig. 6).
Two of the families shared the same large deletion that
included the whole of the CDH3 gene and the ﬁrst two
exons of CDH1. Individuals with homozygous germline
truncating mutations in the CDH3 gene present with hypo-
trichosis with juvenile macular dystrophy (HJMD) syn-
drome (36,37). Heterozygous carriers of such mutations
are phenotypically normal and have not been reported to
have increased GC risk. Haplotype analysis supports a
shared ancestor as the source of the (chr16:67193822–
67387415) in these two families. We have previously used
this approach to demonstrate that recurrent HDGC associ-
ated CDH1 germline point mutations can arise from a
common ancestor (6).
In conclusion, 6.5% of probands from strictly deﬁned
HDGC families who previously tested negative for CDH1
mutations carried heterozygous germline deletions. As these
can be readily identiﬁed using MLPA, an assay frequently
used in clinical cancer genetics laboratories, we suggest that
MLPA be added to the testing strategy for all families who
meet clinical criteria for HDGC.
MATERIALS AND METHODS
Patients and families
The collection of clinical data and peripheral blood samples
was approved by the appropriate Ethics Committee from
each of the centers participating in this work: University of
British Columbia, Vancouver, Canada; Institute of Molecular
Pathology and Immunology, University of Porto, Porto, Portu-
gal; Department of Human Pathology and Oncology, Section
of Surgical Oncology, Translational Research Laboratory,
University of Siena, Italy; Institute of Pathology, Technische
Universita ¨t Mu ¨nchen, Munich, Germany; Department of
Oncology, University of Cambridge, Cambridge, UK. A
series of 160 probands from families with aggregation of
DGC was analyzed in this study, based on the following clini-
cal criteria: (i) three or more DGC in ﬁrst degree relatives
diagnosed at any age or; (ii) two or more GC in ﬁrst degree
relatives with at least one DGC diagnosed before age 50
(see Table 1). From these 160 probands, 67 showed point
mutations in the CDH1 gene and were used only for analysis
of general frequency of CDH1 mutations within HDGC
families. The majority of these families have been published
elsewhere (3,6,10–13,38–46) except for 15 families from
University of British Columbia, Vancouver, Canada (unpub-
lished data DGH), six families from Department of Oncology,
University of Cambridge, Cambridge (unpublished data CC)
and two families from Technische Universita ¨t Mu ¨nchen,
Munich, Germany (unpublished data GK). The remaining 93
probands belonged to families that tested negative for CDH1
germline point mutations. These were analyzed for CDH1
genomic rearrangements.
Peripheral blood leukocytes from the 93 negative probands
were referred for analysis at the different centers. High mol-
ecular weight genomic DNA was isolated from all patients
using standard methodologies.
Multiplex ligation-dependent probe ampliﬁcation
A series of 93 probands, negative for CDH1 germline point
mutations, were tested for the presence of large genomic altera-
tions at the CDH1 locus using MLPA. MLPA is a PCR-based
technique for identifying gene dosage alterations, which has
been previously described in detail (47). All reagents were pro-
vided by the manufacturer in a kit (SALSA P085 CDH1 MLPA
1552 Human Molecular Genetics, 2009, Vol. 18, No. 9kit; MRC-Holland, Amsterdam, Holland), and testing was per-
formed according to the manufacturer’s recommendations.
The assay contains probes for all but one of the CDH1 exons.
For technical reasons exon 8 has been excluded and exon 1
has three different probes. The assay was done according to
manufacturer’sinstructions.Brieﬂy,theprobeswerehybridized
overnight at 608C with 100 ng of germline DNA and sub-
sequently ligated. Ten microliters of the ligation reaction was
used in the PCR which contained FAM labeled primers. The
PCR products were analyzed on an ABI 3130 L Genetic Ana-
lyzer. The output for each patient displayed a peak that corre-
sponded to the amount of ampliﬁed ligated probe present for
eachexonoftheCDH1gene,alongwithseveralpeaksrepresen-
tative of extragenic regions used for ligation and PCR monitor-
ing controls. Peak heights for fragments corresponding to
speciﬁc exons and control regions were binned, appended to a
table,andthensavedasatextﬁle,allwithintheAppliedBiosys-
tems Genotyper software. The resulting data were analyzed
using the Coffalyser software downloaded from MRC-Holland.
Anyexonwithadecrease orincreaseinpeakheightof70%was
scored as a deletion or duplication, respectively. MLPA assays
which showed a variation between peak ratios were repeated.
Comparative genomic hybridization microarray
A CGH array strategy was done to conﬁrm the deletions ident-
iﬁed by MLPA and to identify the location of deletion break-
points. Custom CGH arrays were designed using Agilent’s
eArray program. An 8 15K array format was generated
with Agilent HD CGH Database Catalog Probes for coverage
of chromosome 16: 066880834–067879823. Genomic DNA
(1.5 mg) was labeled using the Agilent Genomic DNA Label-
ing Kit PLUS (Agilent Technologies, Santa Clara, CA).
Samples labeled with Cy3 were co-hybridized with Cy5
labeled gender-matched normal reference gDNA (Promega,
Madison WI) to custom 8 15K Agilent human CGH microar-
rays. Microarrays were washed with Agilent CGH wash
buffers and scanned on an Agilent DNA Microarray
Scanner. Images were analyzed using Agilent Feature Extrac-
tion (version 8.5) and data were analyzed using Agilent CGH
Analytics (version 3.4.27).
Breakpoint identiﬁcation
Based on the information obtained from the CGH array,
primers were designed spanning the putative breakpoints for
each case and used in long-range PCR. A table with primer
sequences is supplied as supplementary material (Supplemen-
tary Material, Table S1).
Haplotype analysis
Analysis was performed using the following microsatellite
markers surrounding the CDH1 gene: D16S318, D16S3107,
D16S3025, D16S496, D16S3067, D16S3095 and D16S752.
Each marker was ampliﬁed and then analyzed on an ABI
3130 L Genetic Analyzer followed by analysis using Gene-
mapper V7.0 software. Primer sequences for the microsatellite
markers D16S3025, D16S496, D16S3095 and D16S752 have
been previously reported (11). Sequences for the remaining
markers, D16S318, D16S3107 and D16S3067 are listed in
the genome database (http://www.gdb.org).
Analysis of breakpoints sequence context
Breakpoints were deﬁned as a set of coordinates on the
genome spanning the genomic sequence of the deletions.
The coordinates have been loaded on the UCSC genome
browser as a BED ﬁle accessible on http://biodev.cbm.fvg.it/
remo/DEL.txt. Both automatic and manual bioinformatics
analysis have been carried out in order to analyze the
genomic context of these regions.
For each deletion we analyzed the closest repeats in a range
of 1500 bp ﬂanking the start/end points. Repeats were
obtained from the Ensembl Homo sapiens core database
version 50 and UCSC genome browser Human Mar. 2006
Assembly. Sequences in a range of 2150/þ50 bp ﬂanking
the start-point and 250/þ150 bp ﬂanking the end-point of
the deletions have been collected in order to test the similarity
around the breakpoints by using both clustalw and blast2 with
default parameters. An interval of 5 Mb around the deletion
start/end points has been analyzed in order to look for the pre-
sence of the RAG1 binding site on both strands by using a
custom perl script and known consensus sequences
(CACTGTG.f11,13gGGTTTTTGT,GGTTTTTGT.f11,13gCA-
CTGTG, ACAAAAACC.f11,13gCACAGTG,CACAGTG.f11,
13gACAAAAACC,CACTGTG.f22,24gGGTTTTTGT,GGTT-
TTTGT.f22,24gCACTGTG,ACAAAAACC.f22,24gCACAGT
G,CACAGTG.f22,24gACAAAAACC). In order to perform
randomization analysis we collected 150 000 random points
on the human genome and calculated for each of them the dis-
tance from the closest Alu. The distribution of the distances
has been trimmed in order to avoid considering points in
poorly annotated regions and/or in gene deserts and/or in
genomic gaps, which resulted nonetheless to be very far
from Alus. We trimmed out all the points retaining a distance
bigger than 4519 bp (the 1.5 IQR of the distribution of all the
distances) from the closest Alu.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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